…
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Insulet Corporation designs and markets the Omnipod tubeless insulin delivery systems and companion software, selling disposable pods that create recurring revenue and integrated automated insulin-delivery solutions for people with insulin-dependent diabetes. Long-term growth may be supported by adoption of Omnipod 5 and AID systems, international expansion, increased conversion from injections to pumps, and predictable consumable demand, which could improve revenue visibility and market share.
Material risks include intense competition from established pump and CGM vendors, reimbursement and regulatory setbacks, manufacturing or supply-chain disruptions, and execution risk in scaling international distribution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 9.80M | 20.50M | 9.70M | 14.50M | 5.23M |
| Net income | 4.60M | 16.80M | 6.80M | 11.60M | 3.29M |
| Selling general administrative | 587.80M | 466.00M | 384.00M | 115.50M | 111.82M |
| Selling and marketing expenses | - | - | - | 185.10M | 142.32M |
| Gross profit | 805.60M | 752.10M | 582.30M | 480.30M | 370.17M |
| Reconciled depreciation | 63.20M | 57.40M | 55.40M | 27.90M | 15.65M |
| Ebit | -26.70M | 66.70M | -0.60M | 22.10M | 11.78M |
| Ebitda | 36.50M | 124.10M | 54.80M | 50.00M | 27.42M |
| Depreciation and amortization | 63.20M | 57.40M | 55.40M | 27.90M | 15.65M |
| Non operating income net other | -1.10M | -44.30M | 3.30M | -0.90M | 6.71M |
| Operating income | -26.70M | 66.70M | -0.60M | 22.10M | 27.42M |
| Other operating expenses | 1267.70M | 972.80M | 852.90M | 688.20M | 536.40M |
| Interest expense | 26.70M | 61.20M | 45.10M | 26.80M | 22.20M |
| Tax provision | 5.20M | 3.70M | 2.90M | 2.90M | 1.93M |
| Interest income | 9.80M | 0.50M | 3.00M | 7.80M | 6.71M |
| Net interest income | -26.70M | -61.20M | -45.10M | -26.80M | -22.20M |
| Income tax expense | 5.20M | 3.70M | 2.90M | 2.90M | 1.93M |
| Total revenue | 1305.30M | 1098.80M | 904.40M | 738.20M | 563.82M |
| Total operating expenses | 768.00M | 626.10M | 530.80M | 430.30M | 342.75M |
| Cost of revenue | 499.70M | 346.70M | 322.10M | 257.90M | 193.66M |
| Total other income expense net | 36.50M | -46.20M | 10.30M | -7.60M | -22.20M |
| Net income from continuing ops | 4.60M | 16.80M | 6.80M | 11.60M | 3.29M |
| Net income applicable to common shares | 4.60M | 16.80M | 6.80M | 11.60M | 3.29M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2588.20M | 2251.10M | 2048.80M | 1872.90M | 1142.90M |
| Intangible assets | 98.70M | 75.50M | 36.60M | 28.70M | 13.20M |
| Other current assets | 99.80M | 86.90M | 74.00M | 63.00M | 31.10M |
| Total liab | 1855.50M | 1774.70M | 1492.50M | 1269.30M | 1067.00M |
| Total stockholder equity | 732.70M | 476.40M | 556.30M | 603.60M | 75.90M |
| Deferred long term liab | - | 31.30M | 26.10M | 21.90M | 19.90M |
| Other current liab | 363.70M | 306.40M | 166.00M | 138.10M | 103.20M |
| Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings | -378.00M | -584.30M | -649.50M | -666.30M | -672.00M |
| Other liab | - | 8.30M | 14.90M | 17.80M | 7.00M |
| Good will | 51.70M | 51.70M | 39.80M | 39.80M | 39.80M |
| Other assets | 0.00M | 147.10M | 106.10M | 79.00M | 25.00M |
| Cash | 650.70M | 674.70M | 791.60M | 947.60M | 376.10M |
| Total current liabilities | 451.20M | 364.70M | 228.80M | 207.80M | 157.70M |
| Current deferred revenue | 15.40M | - | - | - | - |
| Net debt | 798.10M | 727.10M | 457.20M | 96.10M | 511.80M |
| Short term debt | 52.90M | 27.50M | 25.10M | 15.60M | - |
| Short long term debt | 49.40M | 27.50M | 25.10M | 15.60M | - |
| Short long term debt total | 1448.80M | 1401.80M | 1248.80M | 1043.70M | 887.90M |
| Other stockholder equity | 1102.60M | 1040.60M | 1207.90M | 1264.30M | 749.00M |
| Property plant equipment | - | 599.90M | 536.50M | 478.70M | 399.40M |
| Total current assets | 1566.30M | 1314.00M | 1329.80M | 1248.70M | 591.00M |
| Long term investments | - | - | - | 0.00M | 58.40M |
| Net tangible assets | - | 349.20M | 479.90M | 535.10M | 22.90M |
| Short term investments | 53.50M | - | 0.00M | 40.40M | 162.40M |
| Net receivables | 359.70M | 205.60M | 161.00M | 83.80M | 82.80M |
| Long term debt | 1366.40M | 1374.30M | 1248.80M | 1043.70M | 887.90M |
| Inventory | 402.60M | 346.80M | 303.20M | 154.30M | 101.00M |
| Accounts payable | 19.20M | 30.80M | 37.70M | 54.10M | 54.50M |
| Accumulated other comprehensive income | 8.00M | 20.00M | -2.20M | 5.50M | -1.20M |
| Common stock total equity | - | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings total equity | - | -584.30M | -649.50M | -666.30M | -672.00M |
| Non currrent assets other | 178.70M | 210.00M | 106.10M | 77.00M | 41.10M |
| Non current assets total | 1021.90M | 937.10M | 719.00M | 624.20M | 551.90M |
| Long term debt total | - | 1374.30M | 1248.80M | 1043.70M | 887.90M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -176.20M | -7.80M | 40.00M | 180.50M | 97.30M |
| Change to liabilities | - | 131.50M | 8.80M | 34.90M | 41.30M |
| Total cashflows from investing activities | - | -191.10M | -82.70M | 14.00M | -73.60M |
| Net borrowings | - | -39.80M | -464.90M | 128.30M | 31.20M |
| Total cash from financing activities | -13.60M | -40.30M | 40.70M | 605.50M | 73.50M |
| Change to operating activities | - | 100.80M | -22.30M | -4.40M | -16.80M |
| Net income | 206.30M | 4.60M | 16.80M | 6.80M | 11.60M |
| Change in cash | 14.50M | -116.70M | -115.60M | 708.30M | 99.80M |
| Begin period cash flow | 689.70M | 806.40M | 922.00M | 213.70M | 113.90M |
| End period cash flow | 704.20M | 689.70M | 806.40M | 922.00M | 213.70M |
| Total cash from operating activities | 145.70M | 119.00M | -68.10M | 84.00M | 98.40M |
| Issuance of capital stock | - | 0.00M | 0.00M | 477.50M | 50.90M |
| Depreciation | 72.80M | 63.20M | 57.40M | 55.40M | 27.90M |
| Other cashflows from investing activities | -33.60M | -40.00M | 29.20M | -166.50M | -7.20M |
| Dividends paid | 10.60M | - | 23.50M | 98.50M | 8.60M |
| Change to inventory | -53.60M | -49.10M | -154.40M | -50.50M | -30.20M |
| Change to account receivables | -154.20M | -51.80M | -71.30M | -15.60M | -10.90M |
| Sale purchase of stock | 10.60M | -16.80M | -28.20M | -29.80M | -8.60M |
| Other cashflows from financing activities | -13.50M | -0.50M | -8.70M | 1.40M | 703.40M |
| Change to netincome | - | 47.90M | 81.10M | 40.00M | 43.00M |
| Capital expenditures | 75.60M | 157.30M | 122.70M | 166.50M | 170.90M |
| Change receivables | - | -51.80M | -71.30M | -15.60M | - |
| Cash flows other operating | - | -33.10M | -46.70M | -32.20M | -30.80M |
| Cash and cash equivalents changes | - | -112.40M | -110.10M | 703.50M | 98.30M |
| Change in working capital | -190.60M | -2.50M | -263.60M | -63.40M | -19.70M |
| Stock based compensation | 48.30M | 40.90M | 34.40M | 35.90M | 28.70M |
| Other non cash items | 8.90M | 12.80M | 41.40M | 46.00M | 36.70M |
| Free cash flow | 36.50M | -38.30M | -190.80M | -82.50M | -72.50M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PODD Insulet Corporation |
-0.48 0.32% |
149.55 | 47.03 | 70.92 | 9.76 | 17.30 | 10.00 | 47.76 |
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. James R. Hollingshead Ph.D. | Pres, CEO & Director | 1963 |
| Mr. Wayde D. McMillan | Exec. VP,CFO & Treasurer | 1970 |
| Mr. Charles Alpuche | Exec. VP & COO | 1960 |
| Mr. John Wodick Kapples | Sr. VP & Gen. Counsel | 1960 |
| Ms. Shacey Petrovic | Director & Advisor | 1974 |
| Mr. Bret Christensen | Exec. VP & Chief Commercial Officer | 1971 |
| Ms. Lauren Budden | VP, Chief Accounting Officer & Controller | NA |
| Ms. Deborah R. Gordon CPA | VP of Investor Relations | 1970 |
| Mr. Michael Spears | Sr. VP of Regulatory Affairs & Compliance | 1965 |
| Angela Geryak Wiczek | Sr. Director of Corp. Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.